Q
6.87
-0.78 (-10.20%)
| Previous Close | 7.65 |
| Open | 7.16 |
| Volume | 126,371 |
| Avg. Volume (3M) | 367,532 |
| Market Cap | 4,040,707 |
| Price / Book | 0.390 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -66.85 |
| Total Debt/Equity (MRQ) | 31.76% |
| Current Ratio (MRQ) | 3.57 |
| Operating Cash Flow (TTM) | -7.86 M |
| Levered Free Cash Flow (TTM) | -4.28 M |
| Return on Assets (TTM) | -42.72% |
| Return on Equity (TTM) | -120.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Quoin Pharmaceuticals, Ltd. | Mixed | Mixed |
AIStockmoo Score
0.4
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 7.08% |
| % Held by Institutions | 7.60% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |